Clinical Trial Update: Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety and efficacy of autologous CD34+ cells transduced with the GLOBE1 lentiviral vector expressing βAS3 globin for sickle cell dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• GLOBE1 lentiviral vector expressing βAS3 globin (lentiviral vector encoding βAS3 globin gene)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED